RESOURCES

May 06, 2025

Share

Targeted B-Cell Therapies: Challenges and Preclinical Evaluation Considerations for Repurposing from Oncology to Autoimmunity

While targeted therapies such as B-cell depletion and immune modulation have revolutionized treatment for B-cell malignancies, recent efforts to repurpose these therapies for autoimmune diseases, for example systemic lupus erythematosus (SLE), have gained traction. However, translating oncology-focused B-cell therapies to autoimmune diseases requires addressing fundamental differences in disease pathophysiology, therapeutic goals, and safety profiles. In this webinar, we will outline key challenges and preclinical evaluation considerations to help you navigate this cross-disciplinary transition.